TNFSF10 and acute myeloid leukemia: In summary, the combination of RO‐BIR2 with TRAIL or Ara‐C represents a potent therapeutic strategy for AML, and properly designed clinical trials of these combinations are essential to validate the synergistic benefits in patients with AML, especially for the elderly, who are less tolerable to intensive chemotherapy.